SCHEMBL30744002

SCHEMBL30744002

Cc1cc(NC(=O)Nc2ccc(F)cc2)ccc1Oc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK39 Q9UEW8 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
IDH1 O75874 1/20 0.50
DHODH Q02127 1/20 0.50
PGR P06401 1/20 0.49
AR P10275 1/20 0.49
PNLIP P16233 1/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
P2RY1 P47900 1/20 0.48
KDR P35968 2/20 0.48
PDGFRA P16234 1/20 0.48
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21295337 1.00 STK39 (0.54) STK39SMN1; SMN2NPC1RAB9AIDH1
SCHEMBL21295431 0.92 STK39 (0.58) STK39SMN1; SMN2NPC1RAB9AIDH1
SCHEMBL30744028 0.92 STK39 (0.60) STK39SMN1; SMN2NPC1RAB9AIDH1
SCHEMBL21305446 0.92 STK39 (0.60) STK39SMN1; SMN2NPC1RAB9AIDH1
SCHEMBL21295331 0.89 STK39 (0.56) STK39NPC1RAB9AIDH1DHODH
SCHEMBL30743992 0.86 TP53 (0.64) SMN1; SMN2NPC1RAB9APGRAR
SCHEMBL21295385 0.86 TP53 (0.64) SMN1; SMN2NPC1RAB9APGRAR
SCHEMBL30743998 0.85 STK39 (0.57) STK39SMN1; SMN2NPC1RAB9AIDH1
SCHEMBL21295557 0.85 STK39 (0.57) STK39SMN1; SMN2NPC1RAB9AIDH1
SCHEMBL21295412 0.84 STK39 (0.62) STK39SMN1; SMN2NPC1RAB9ADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111819172-B Triazine derivatives for the treatment of neurotrophin related diseases 阿泽克制药公司 2024-02-06 CN disclosed